Roche, Merck to collaborate to develop companion diagnostic test

Roche (RHHBY) announced that it entered into a collaboration with Merck (MRK) to develop a companion diagnostic test to identify patients eligible for anti-PD-1 therapy based on the status of a biomarker in advanced solid tumors. The companies will collaborate on the development of a pan-cancer companion diagnostic to detect mismatch repair deficiency in solid tumors. The companion diagnostic currently under development is an IHC test for use on the Roche BenchMark ULTRA instrument, which, as the most widely installed IHC/ISH staining platform globally, will provide broad testing access to patients.
https://thefly.com/landingPageNews.php?id=2835445